PDT Partners’s ImmunityBio IBRX Stock Holding History

PDT Partners’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-44,814	Closed	-$311K	–	763
2020 Q3	$311K	Buy	+44,814	New	+$447K	0.02%	547

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

PDT Partners's IBRX Position: Q4 2020 in Review

PDT Partners sold out of ImmunityBio (IBRX) in Q4 2020, closing a stake of 44,814 shares — an estimated $311K sold.

PDT Partners first reported a position in IBRX in Q3 2020 and held it in 1 quarter. The position peaked at $311K in Q3 2020. 104 funds tracked by Wall St. Rank hold IBRX as of Q4 2020.

PDT Partners reported no remaining ImmunityBio position as of Q4 2020 after selling out during the quarter.
PDT Partners sold 44,814 ImmunityBio shares in Q4 2020, an estimated $311K.
PDT Partners first reported a position in ImmunityBio in Q3 2020 and held it in 1 quarter.
PDT Partners's ImmunityBio position peaked at $311K in Q3 2020.
104 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2020.

Based on PDT Partners's 13F filing for Q4 2020, filed 16 Feb 2021.